Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent

Samaneh Zolghadri; Amir Reza Jalilian; Hassan Yousefnia; Ali Bahrami-Samani; Mohammad Ghannadi-Maragheh

doi:10.4103/1450-1147.138571

Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent

World J Nucl Med. 2014 Jan;13(1):28-33. doi: 10.4103/1450-1147.138571.

Authors

Samaneh Zolghadri¹, Amir Reza Jalilian¹, Hassan Yousefnia¹, Ali Bahrami-Samani¹, Mohammad Ghannadi-Maragheh¹

Affiliation

¹ Radiopharmacy Research Group, Radiation Application Research School, Nuclear Science and Technology Research Institute, P.O.Box:14395-836, Tehran, Iran.

Abstract

(166)Holmium-1,2-propylene di-amino tetra (methy1enephosphonicacid) ((166) Ho-PDTMP) complex was prepared successfully using an in-house synthesized PDTMP ligand and (166) HoCl 3 . Ho-166 chloride was obtained by thermal neutron irradiation (1 × 10 (13) n/cm (2) /s) of natural Ho (NO 3 ) 3 samples (specific activity = 3-5 GBq/mg), dissolved in acidic media. Radiochemical purity of (166) Ho-PDTMP was checked by instant thin layer chromatography (>99%). Stability studies of the complex in the final preparation and in the presence of human serum were performed up to 72 h. The biodistribution of (166) Ho-PDTMP and (166) HoCl 3 in wild-type rats was checked in animal tissues up to 48 h. The produced (166) Ho-PDTMP properties suggest a possible new bone palliative therapeutic to overcome the metastatic bone pains.

Keywords: 166Ho-PDTMP; 166Holmium; biodistribution; radiopharmaceutical.

Publication types

Retracted Publication